Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;102:e119
doi: 10.1161/CIRCRESAHA.108.178715
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, G.
Right arrow Articles by Hayden, M. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Liu, G.
Right arrow Articles by Hayden, M. R.
(Circulation Research. 2008;102:e119.)
© 2008 American Heart Association, Inc.


Letters to the Editor

Response to the Letter by Ebara et al

George Liu

Institute of Cardiovascular Sciences, Peking University, Beijing, China

Michael R. Hayden

Department of Medical Genetics, University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada, E-mail mrh{at}cmmt.ubc.ca

As highlighted by Dr Ebara et al, there are key differences in lipoprotein metabolism between mice and humans. In humans, lipoprotein lipase (LPL) deficiency with severe hypertriglyceridemia was originally reported to be nonatherogenic.1 However, in 1996, Benlian et al presented 4 French cases of LPL deficiency with severe hypertriglyceridemia who all displayed various degrees of angiographically defined coronary or carotid atherosclerosis.2 One of them had bypass surgery at age 65, and during the surgery, atherosclerotic lesions of all grades (from fatty streaks to calcified and hemorrhagic atherosclerotic plaques) were noted all along the aorta and iliac and femoral arteries. The patient died suddenly 2 years after surgery. These 4 cases not only exhibited severe hypertriglyceridemia, but they also had high cholesterol levels, which were elevated 3- to 4-fold over the normal range, because even in triglyceride-rich lipoproteins, there is a certain portion of cholesterol and its esters consisting of lipid core.

Over the past decade, there have been several case reports of LPL-deficient patients with or without detectable lesions of atherosclerosis.3,4 Therefore, humans with LPL-deficient hypertriglyceridemia appear to be prone to atherosclerosis in certain circumstances. As discussed in our article,5 such discrepancies between different individuals may be partially explained by the presence or absence of noncatalytic LPL protein. The catalytically inactive LPL protein could act as a molecular bridge between proteoglycans and different lipoprotein receptors to facilitate lipoprotein uptake by cells such as macrophages. Therefore, if macrophage secrete inactive LPL protein, such molecules may then enhance foam cell formation through increased uptake of atherogenic lipoproteins.

We also found that LPL-deficient mice developed spontaneous atherosclerosis only at a very old age. The extent of lesions in these mice were equivalent to those of apolipoprotein E–null mice at {approx}3 months of age (G. Liu, personal communication, 2005). Similarly, the patients with LPL-deficient hypertriglyceridemia reported by Benlian et al manifested signs of peripheral atherosclerosis or CAD at age 50, which is in contrast to familial hypercholesterolemia patients who have signs of atherosclerosis at very early age.6

In the aged LPL-deficient mice, there was a marked increase in oxidative susceptibility of chylomicrons, and in vitro evidence that these chylomicrons increased the expression of vascular cell adhesion molecules. Although the spontaneous atherosclerosis found in old LPL-deficient mice in our study may not directly extrapolate to humans with LPL deficiency, these results provide insight into the potential mechanisms of the variable susceptibility to atherosclerosis in LPL-deficient patients.

Regarding the nature of accumulated triglyceride-rich lipoproteins in LPL-deficient mice, these particles do not consist of very-low-density lipoprotein alone, but instead they are a mixture of chylomicrons, chylomicron remnants, and very-low-density lipoprotein, because a large portion of these lipoproteins could be floated by centrifugation in a Hitachi P42AT rotor at 25 000 rpm (75 700g) for 20 minutes at 15°C, as described in the expanded Materials and Methods section in the online data supplement of our article.5 The fractions isolated by this way are mainly composed of chylomicrons and chylomicron remnants.7 Although these lipoproteins may not enter arterial wall, modified chylomicron and remnants, especially oxidized forms of these triglyceride-rich lipoproteins, will activate endothelial cells, which will ultimately result in development of atherosclerosis, as evidenced by our experiments. Although HDL cholesterol levels in these mice are extremely low, their LDL cholesterol levels are similar to wild type as a barely discernable peak in fast protein liquid chromatography profile.

Therefore, the message from our article and from this discussion is that patients with LPL deficiency are not free of atherosclerotic disorders. They may actually well be at increased risk of atherosclerosis, especially at later stages of life.

Acknowledgments

Sources of Funding

Supported by Canadian Institutes of Health Research (CIHR), China-Canada Collaboration.

Disclosures

None.

References

1. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. Vol 2. New York: McGraw-Hill; 1995: 1913–1932.

2. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med. 1996; 335: 848–854.[Abstract/Free Full Text]

3. Saika Y, Sakai N, Takahashi M, Maruyama T, Kihara S, Ouchi N, Ishigami M, Hiraoka H, Nakamura T, Yamashita S, Matsuzawa Y. Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis. Eur J Clin Invest. 2003; 33: 216–222.[CrossRef][Medline] [Order article via Infotrieve]

4. Ebara T, Okubo M, Horinishi A, Adachi M, Murase T, Hirano T. No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61-Stop) in the lipoprotein lipase gene. Atherosclerosis. 2001; 159: 375–379.[CrossRef][Medline] [Order article via Infotrieve]

5. Zhang X, Qi R, Xian X, Yang F, Blackstein M, Deng X, Fan J, Ross C, Karasinska J, Hayden MR, Liu G. Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circ Res. 2008; 102: 250–256.[Abstract/Free Full Text]

6. Wiegman A, Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJG, Kastelein JJP. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004; 363: 369–370.[CrossRef][Medline] [Order article via Infotrieve]

7. Bhattacharya S, Redgrave TG. The content of apolipoprotein B in chylomicron particles. J Lipid Res. 1981; 22: 820–828.[Abstract]





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, G.
Right arrow Articles by Hayden, M. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Liu, G.
Right arrow Articles by Hayden, M. R.